---
title: "Vicore to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference"
date: "2025-02-10 15:30:58"
summary: "STOCKHOLM, SE / ACCESS Newswire / February 10, 2025 / Vicore Pharma Holding (STO:VICO)Stockholm, February 10, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, will present..."
categories:
  - "morningstar"
lang:
  - "en"
translations:
  - "en"
tags:
  - "morningstar"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

**STOCKHOLM, SE / [ACCESS Newswire](https://www.accessnewswire.com/) / February 10, 2025 /** Vicore Pharma Holding (STO:VICO)

**Stockholm, February 10, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference.**

* **Presentation Date and Time:** Wednesday, February 12, 2025, at 8:00 AM ET/2:00 PM CET
* **Presenter:** Ahmed Mousa, CEO
* **Webcast:** [https://wsw.com/webcast/oppenheimer39/vico/2791144](https://pr.report/6zzn)

Interested parties may also access the webcast replay on Vicore's [website](https://pr.report/6zzo) for 90 days following the conclusion of the event.  
  
**For further information, please contact:**  
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, [megan.richards@vicorepharma.com](mailto:megan.richards@vicorepharma.com)  
Hans Jeppsson, CFO, tel: +46 70 553 14 65, [hans.jeppsson@vicorepharma.com](mailto:hans.jeppsson@vicorepharma.com)

**About Vicore Pharma**  
*Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.*  
  
*The company is publicly listed on the Nasdaq Stockholm exchange (VICO).* [*www.vicorepharma.com*](https://pr.report/6zzp)

**Attachments**  
[Vicore to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference](https://pr.report/6zzq)

**SOURCE:** Vicore Pharma Holding

  
  
View the original [press release](https://www.accessnewswire.com/newsroom/en/biotechnology/vicore-to-present-at-oppenheimers-35th-annual-healthcare-life-sciences-conference-982424) on ACCESS Newswire  
  

 ![](https://app.accessnewswire.com/img.ashx?id=982424)

[morningstar](https://www.morningstar.com/news/accesswire/982424msn/vicore-to-present-at-oppenheimers-35th-annual-healthcare-life-sciences-conference)
